« Return to News | Clinical Intelligence

Lexicon’s LX411 enhances DPP-4 inhibitor in type 2 diabetics

Friday, January 13, 2012 12:09 PM

LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, was proven to enhance the affects of widely prescribed diabetes drug sitagliptin, a DDP-4 (dipeptidyl peptidase) inhibitor, reported Lexicon Pharmaceuticals.

Results of the study showed 18 patients with type 2 diabetes given single doses of LX4211 in combination with sitagliptin produced lower blood glucose levels after meals (postprandial) as compared to being treated with sitagliptin alone.

"Alone, LX4211 produces rapid improvement in postprandial blood glucose by delaying intestinal glucose absorption and increasing urinary glucose excretion,” said Dr. Pablo Lapuerta, senior vice president of clinical development and chief medical officer at Lexicon. “When combined, the two agents produce enhanced benefits on blood glucose, insulin, GLP-1 and PYY relative to sitagliptin alone, suggesting these agents work together and could provide additional benefits for patients with type 2 diabetes."

The study was design to assess pharmacodynamic parameters, including postprandial glucose, insulin, total and active GLP-1, PYY and urinary glucose excretion.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.